Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATACC AML
NCT03568994Phase 1Completed
- Sponsor
- Baylor College of Medicine
- Start
- Jul 2018
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of atovaquone in Pneumocystis jirovecii pneumonia (PCP) (2 arms), sponsored by Baylor College of Medicine. Primary endpoints: Steady-state plasma levels of atovaquone at 5 weeks, Frequency of omission of atovaquone doses at 5 weeks and 1 more. Started Jul 2018; status: completed.
02
Drugs
atovaquone
03
Conditions
Pneumocystis jirovecii pneumonia (PCP)
Beyond the preview
Go deeper on NCT03568994.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03568994.